Clinical trial Recruiting at 3 sites Interventional Ages 18 to 80

Imaging CXCR4-related diseases using PET/CT

Official title: Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

Run by Tianjin Medical University · NCT06690736 · Data updated 2026-11-12

This study is testing a new type of imaging to see if it can better identify and track diseases related to CXCR4 in patients.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment200 (estimated)
SponsorTianjin Medical University
Academic / other
Locations3 sites (Hefei, Anhui and 2 other locations)
StatusRecruiting
StartedMarch 1, 2022
Main results expectedOctober 1, 2027
Study endsOctober 1, 2027
Registry record updatedSeptember 8, 2026
Trial IDNCT06690736 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with suspected or confirmed untreated lymphoproliferative and other CXCR4-related diseases.

Probably not a fit

Patients who are pregnant, breastfeeding, or have a known allergy to Pentixafor may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with CXCR4-related diseases. Participants will undergo PET/CT imaging to assess the uptake of the tracer in lesions, with results analyzed for sensitivity, specificity, and accuracy. The goal is to determine how well this imaging technique can identify and monitor these diseases.

Why it matters

Potential benefit: If successful, this imaging technique could improve the diagnosis and monitoring of CXCR4-related diseases, leading to better patient outcomes.

How similar studies have gone: Other studies have shown promising results with similar imaging approaches, indicating potential for success in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
* 18F-FDG PET/CT within two weeks
* signed written consent.

Exclusion Criteria:

* pregnancy
* breastfeeding
* known allergy against Pentixafor

Where it's running

  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui, China
    Recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Recruiting
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.